1. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9, 271-296.
2. Piccioli, D.; Tavarini, S.; Borgogni, E.; Steri, V.; Nuti, S.; Sammicheli, C.; Bardelli, M.; Montagna, D.; Locatelli, F.; Wack, A. Functional specialization of human circulating cd16 and cd1c myeloid dendritic-cell subsets. Blood 2007, 109, 5371-5379.
3. Lindstedt, M.; Lundberg, K.; Borrebaeck, C.A. Gene family clustering identifies functionally associated subsets of human in vivo blood and tonsillar dendritic cells. J Immunol 2005, 175, 4839-4846. 4. Schreibelt, G.; Tel, J.; Sliepen, K.H.; Benitez-Ribas, D.; Figdor, C.G.; Adema, G.J.; de Vries, I.J. Toll-
like receptor expression and function in human dendritic cell subsets: Implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010, 59, 1573-1582. 5. Trinchieri, G. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory
functions in the generation of t-helper cells type 1 and cytotoxic lymphocytes. Blood 1994, 84, 4008-4027.
6. Jarrossay, D.; Napolitani, G.; Colonna, M.; Sallusto, F.; Lanzavecchia, A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. European journal of immunology 2001, 31, 3388-3393.
7. Cella, M.; Jarrossay, D.; Facchetti, F.; Alebardi, O.; Nakajima, H.; Lanzavecchia, A.; Colonna, M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type i interferon. Nat Med 1999, 5, 919-923.
8. Kadowaki, N.; Antonenko, S.; Lau, J.Y.; Liu, Y.J. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. The Journal of experimental medicine 2000, 192, 219-226. 9. Ackerman, A.L.; Kyritsis, C.; Tampe, R.; Cresswell, P. Access of soluble antigens to the endoplasmic
reticulum can explain cross-presentation by dendritic cells. Nature immunology 2005, 6, 107-113. 10. Di Pucchio, T.; Chatterjee, B.; Smed-Sorensen, A.; Clayton, S.; Palazzo, A.; Montes, M.; Xue, Y.;
Mellman, I.; Banchereau, J.; Connolly, J.E. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class i. Nature immunology 2008, 9, 551-557.
11. Huang, A.Y.; Bruce, A.T.; Pardoll, D.M.; Levitsky, H.I. In vivo cross-priming of mhc class i-restricted antigens requires the tap transporter. Immunity 1996, 4, 349-355.
12. Shen, L.; Sigal, L.J.; Boes, M.; Rock, K.L. Important role of cathepsin s in generating peptides for tap-independent mhc class i crosspresentation in vivo. Immunity 2004, 21, 155-165.
13. den Haan, J.M.M.; Lehar, S.M.; Bevan, M.J. Cd8+ but not cd8- dendritic cells cross-prime cytotoxic t cells in vivo. The Journal of experimental medicine 2000, 192, 1685-1696.
14. Heath, W.R.; Belz, G.T.; Behrens, G.M.N.; Smith, C.M.; Forehan, S.P.; Parish, I.A.; Davey, G.M.; Wilson, N.S.; Carbone, F.R.; Villadangos, J.A. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 2004, 199, 9-26.
15. Mortellaro, A.; Wong, S.C.; Fric, J.; Ricciardi-Castagnoli, P. The need to identify myeloid dendritic cell progenitors in human blood. Trends in immunology 2010, 31, 18-23.
16. Jongbloed, S.L.; Kassianos, A.J.; McDonald, K.J.; Clark, G.J.; Ju, X.; Angel, C.E.; Chen, C.J.; Dunbar, P.R.; Wadley, R.B.; Jeet, V., et al. Human cd141+ (bdca-3)+ dendritic cells (dcs) represent a unique myeloid dc subset that cross-presents necrotic cell antigens. The Journal of experimental medicine 2010, 207, 1247-1260.
17. Bachem, A.; Guttler, S.; Hartung, E.; Ebstein, F.; Schaefer, M.; Tannert, A.; Salama, A.; Movassaghi, K.; Opitz, C.; Mages, H.W., et al. Superior antigen cross-presentation and xcr1 expression define human cd11c+cd141+ cells as homologues of mouse cd8+ dendritic cells. The Journal of experimental medicine 2010, 207, 1273-1281.
18. Crozat, K.; Guiton, R.; Contreras, V.; Feuillet, V.; Dutertre, C.A.; Ventre, E.; Vu Manh, T.P.; Baranek, T.; Storset, A.K.; Marvel, J., et al. The xc chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse cd8alpha+ dendritic cells. The Journal of experimental medicine 2010, 207, 1283-1292.
19. Poulin, L.F.; Salio, M.; Griessinger, E.; Anjos-Afonso, F.; Craciun, L.; Chen, J.L.; Keller, A.M.; Joffre, O.; Zelenay, S.; Nye, E., et al. Characterization of human dngr-1+ bdca3+ leukocytes as putative equivalents of mouse cd8alpha+ dendritic cells. The Journal of experimental medicine 2010, 207, 1261-1271.
20. Robson, N.C.; McAlpine, T.; Knights, A.J.; Schnurr, M.; Shin, A.; Chen, W.; Maraskovsky, E.; Cebon, J. Processing and cross-presentation of individual hla-a, -b, or -c epitopes from ny-eso-1 or an hla-a epitope for melan-a differ according to the mode of antigen delivery. Blood 2010, 116, 218-225. 21. Schnurr, M.; Chen, Q.; Shin, A.; Chen, W.; Toy, T.; Jenderek, C.; Green, S.; Miloradovic, L.; Drane,
D.; Davis, I.D., et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005, 105, 2465-2472.
22. Villadangos, J.A.; Young, L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008, 29, 352-361.
23. Tel, J.; Lambeck, A.J.; Cruz, L.J.; Tacken, P.J.; de Vries, I.J.; Figdor, C.G. Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol 2010, 184, 4276-4283.
24. Hoeffel, G.; Ripoche, A.C.; Matheoud, D.; Nascimbeni, M.; Escriou, N.; Lebon, P.; Heshmati, F.; Guillet, J.G.; Gannage, M.; Caillat-Zucman, S., et al. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 2007, 27, 481-492.
25. Lui, G.; Manches, O.; Angel, J.; Molens, J.P.; Chaperot, L.; Plumas, J. Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells. PLoS One 2009, 4, e7111.
26. Schreibelt, G.; Klinkenberg, L.J.; Cruz, L.J.; Tacken, P.J.; Tel, J.; Kreutz, M.; Adema, G.J.; Brown, G.D.; Figdor, C.G.; de Vries, I.J. The c type lectin receptor clec9a mediates antigen uptake and (cross-)presentation by human blood bdca3+ myeloid dendritic cells. Blood 2012.
27. Tel, J.; Benitez-Ribas, D.; Hoosemans, S.; Cambi, A.; Adema, G.J.; Figdor, C.G.; Tacken, P.J.; de Vries, I.J. Dec-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. European journal of immunology 2011, 41, 1014-1023.
28. Cruz, L.J.; Iglesias, E.; Aguilar, J.C.; Gonzalez, L.J.; Reyes, O.; Albericio, F.; Andreu, D. A comparative study of different presentation strategies for an hiv peptide immunogen. Bioconjug Chem 2004, 15, 112-120.
29. Schaft, N.; Dörrie, J.; Müller, I.; Beck, V.; Baumann, S.; Schunder, T.; Kämpgen, E.; Schuler, G. A new way to generate cytolytic tumor-specific t cells: Electroporation of rna coding for a t cell receptor into t lymphocytes. Cancer Immunology, Immunotherapy 2006, 55, 1132-1141.
30. Schreibelt, G.; Benitez-Ribas, D.; Schuurhuis, D.; Lambeck, A.J.; van Hout-Kuijer, M.; Schaft, N.; Punt, C.J.; Figdor, C.G.; Adema, G.J.; de Vries, I.J. Commonly used prophylactic vaccines as an alternative for synthetically produced tlr ligands to mature monocyte-derived dendritic cells. Blood 2010, 116, 564-574.
31. Benitez-Ribas, D.; Tacken, P.; Punt, C.J.A.; de Vries, I.J.M.; Figdor, C.G. Activation of human plasmacytoid dendritic cells by tlr9 impairs fc gamma rii-mediated uptake of immune complexes and presentation by mhc class ii. Journal of Immunology 2008, 181, 5219-5224.
32. Kurts, C.; Robinson, B.W.; Knolle, P.A. Cross-priming in health and disease. Nat Rev Immunol 2010, 10, 403-414.
33. Kool, M.; Geurtsvankessel, C.; Muskens, F.; Madeira, F.B.; van Nimwegen, M.; Kuipers, H.; Thielemans, K.; Hoogsteden, H.C.; Hammad, H.; Lambrecht, B.N. Facilitated antigen uptake and timed exposure to tlr ligands dictate the antigen-presenting potential of plasmacytoid dcs. J Leukoc Biol 2011, 90, 1177-1190.
34. Segura, E.; Valladeau-Guilemond, J.; Donnadieu, M.H.; Sastre-Garau, X.; Soumelis, V.; Amigorena, S. Characterization of resident and migratory dendritic cells in human lymph nodes. The Journal of experimental medicine 2012, 209, 653-660.
35. Mouries, J.; Moron, G.; Schlecht, G.; Escriou, N.; Dadaglio, G.; Leclerc, C. Plasmacytoid dendritic cells efficiently cross-prime naive t cells in vivo after tlr activation. Blood 2008, 112, 3713-3722. 36. Benitez-Ribas, D.; Adema, G.J.; Winkels, G.; Klasen, I.S.; Punt, C.J.A.; Figdor, C.G.; de Vries, I.J.M.
Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to cd4+ t cells after fc gamma rii-mediated uptake. The Journal of experimental medicine 2006, 203, 1629-1635.
4
37. Klechevsky, E.; Flamar, A.L.; Cao, Y.; Blanck, J.P.; Liu, M.; O’Bar, A.; Agouna-Deciat, O.; Klucar, P.; Thompson-Snipes, L.; Zurawski, S., et al. Cross-priming cd8+ t cells by targeting antigens to human dendritic cells through dcir. Blood 2011, 116, 1685-1697.
38. Reboulet, R.A.; Hennies, C.M.; Garcia, Z.; Nierkens, S.; Janssen, E.M. Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor- bearing mice. J Immunol 2010, 185, 3337-3347.
39. Karthaus, N.; Torensma, R.; Tel, J. Deciphering the message broadcasted by tumor infiltrating dendritic cells. The American journal of pathology 2012.
40. Wei, S.; Kryczek, I.; Zou, L.; Daniel, B.; Cheng, P.; Mottram, P.; Curiel, T.; Lange, A.; Zou, W. Plasmacytoid dendritic cells induce cd8+ regulatory t cells in human ovarian carcinoma. Cancer Res 2005, 65, 5020-5026.
41. Treilleux, I.; Blay, J.Y.; Bendriss-Vermare, N.; Ray-Coquard, I.; Bachelot, T.; Guastalla, J.P.; Bremond, A.; Goddard, S.; Pin, J.J.; Barthelemy-Dubois, C., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004, 10, 7466-7474.
42. Stary, G.; Bangert, C.; Tauber, M.; Strohal, R.; Kopp, T.; Stingl, G. Tumoricidal activity of tlr7/8- activated inflammatory dendritic cells. The Journal of experimental medicine 2007, 204, 1441-1451. 43. Drobits, B.; Holcmann, M.; Amberg, N.; Swiecki, M.; Grundtner, R.; Hammer, M.; Colonna, M.;
Sibilia, M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pdcs into tumor-killing effector cells. The Journal of clinical investigation 2012.
44. Piccioli, D.; Sammicheli, C.; Tavarini, S.; Nuti, S.; Frigimelica, E.; Manetti, A.G.O.; Nuccitelli, A.; Aprea, S.; Valentini, S.; Borgogni, E., et al. Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood 2009, 113, 4232-4239.
45. Diamond, M.S.; Kinder, M.; Matsushita, H.; Mashayekhi, M.; Dunn, G.P.; Archambault, J.M.; Lee, H.; Arthur, C.D.; White, J.M.; Kalinke, U., et al. Type i interferon is selectively required by dendritic cells for immune rejection of tumors. The Journal of experimental medicine 2011, 208, 1989-2003. 46. Banchereau, J.; Palucka, A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev
Immunol 2005, 5, 296-306.
47. den Brok, M.H.; Nierkens, S.; Figdor, C.G.; Ruers, T.J.M.; Adema, G.J. Dendritic cells: Tools and targets for antitumor vaccination. Expert Rev Vaccines 2005, 4, 699-710.
48. Jonuleit, H.; Giesecke-Tuettenberg, A.; Tuting, T.; Thurner-Schuler, B.; Stuge, T.B.; Paragnik, L.; Kandemir, A.; Lee, P.P.; Schuler, G.; Knop, J., et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific t-cell responses in humans following intranodal injection. International journal of cancer 2001, 93, 243-251.
49. de Vries, I.J.; Lesterhuis, W.J.; Scharenborg, N.M.; Engelen, L.P.; Ruiter, D.J.; Gerritsen, M.J.; Croockewit, S.; Britten, C.M.; Torensma, R.; Adema, G.J., et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003, 9, 5091-5100.
50. Lesterhuis, W.J.; Schreibelt, G.; Scharenborg, N.M.; Brouwer, H.M.; Gerritsen, M.J.; Croockewit, S.; Coulie, P.G.; Torensma, R.; Adema, G.J.; Figdor, C.G., et al. Wild-type and modified gp100 peptide- pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 2011, 60, 249-260.